Vytorin Labeling Shows Superiority To Lipitor, Zocor
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck/Schering-Plough Vytorin sales reps will use clinical data in FDA-approved labeling demonstrating superiority in reducing LDL cholesterol to both Merck's Zocor and Pfizer's Lipitor
You may also be interested in...
Kos’ Niaspan/Simvastatin Combination NDA Planned For 2006
Two pivotal trials for the extended-release niacin/simvastatin fixed-dose combination are underway, Kos says. Firm expects the new combo to be superior to predecessor Advicor in lowering LDL-cholesterol and similar in raising HDL-C.
Kos’ Niaspan/Simvastatin Combination NDA Planned For 2006
Two pivotal trials for the extended-release niacin/simvastatin fixed-dose combination are underway, Kos says. Firm expects the new combo to be superior to predecessor Advicor in lowering LDL-cholesterol and similar in raising HDL-C.
Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds
Merck/Schering's Zocor/Zetia fixed-dose combo is likely to have coverage in one of the top two tiers in up to 50% of managed care plans six to 12 months post-launch, a Prudential survey finds. Crestor has coverage in top two tiers for about 30% of plans after one year on the market.